Therapeutic management of pyoderma gangrenosum

Arthritis and Rheumatism

Volumn 50, Issue 10, 2004, Pages 3076-3084

  Ehling, Angela ^a   Karrer, Sigrid ^a   Klebl, Frank ^a   Schäffler, Andreas ^a   Müller Ladner, Ulf ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BECAPLERMIN; CHLORAMBUCIL; CLOBETASOL PROPIONATE; CLOFAZIMINE; COLLAGEN TYPE 1; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; HYALOGRAN; HYALURONIC ACID; IMMUNOGLOBULIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; SALAZOSULFAPYRIDINE; TACROLIMUS; THALIDOMIDE; UNCLASSIFIED DRUG; WOUND HEALING PROMOTING AGENT;

CENTRAL NERVOUS SYSTEM DISEASE; CORTICOSTEROID THERAPY; DEBRIDEMENT; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DOSE CALCULATION; DRUG EFFICACY; HEMOLYTIC ANEMIA; HISTOPATHOLOGY; HUMAN; HYPERBARIC OXYGEN; HYPERPIGMENTATION; INCIDENCE; LEUKOCYTE COUNT; LIVER TOXICITY; LUPUS LIKE SYNDROME; PARESTHESIA; PATHOGENESIS; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; RELAPSE; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SKIN IRRITATION; SKIN MANIFESTATION; SKIN ULCER; TERATOGENICITY; TOOTH COLOR; TOOTH DISEASE; ULCER HEALING;

HUMANS; PYODERMA GANGRENOSUM;

EID: 5644252977     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20559     Document Type: Review

References (83)

1. Kuner N, Hartschuh W. Description of pyoderma gangrenosum in a dermatologic atlas of the early 19th century. Hautarzt 2000;51:519-23.
2. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma (ecthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syph 1930;22:655-80.
3. Blitz NM, Rudikoff D. Pyoderma gangrenosum. Mt Sinai J Med 2001;68:287-97.
4. Provost TT, Harris ML. Pyoderma gangrenosum. In: Provost TT, Flynn JA, editors. Cutaneous medicine: cutaneous manifestations of systemic disease. Hamilton (Ontario): BC Decker; 2001. p. 464-8.
5. Crowson AN, Mihm MC Jr, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003;30:97-107.
6. Youker SR, Marks JG, Ioffreda MD. Occupationally induced pyoderma gangrenosum. J Am Acad Dermatol 2002;47:322-3.
7. Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000;135:564-8.
8. Mlika RB, Riahi I, Fenniche S, Mokni M, Dhaoui MR, Dess N, et al. Pyoderma gangrenosum: a report of 21 cases. Int J Dermatol 2002;41:65-8.
9. Powell FC, Su WP, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996;34:395-409.
10. Hoffman MD. Pyoderma gangrenosum associated with c-ANCA (h-lamp-2). Int J Dermatol 2001;40:135-7.
11. Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, et al. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers and leads to ulcer formation in human skin xenografts. Lab Invest 2000;80:595-604.
12. Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB Jr, White WL, Callen JP. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000;79:37-46.
13. Patrone P, Bragadin G, De Francesco V, Frattasio A, Stinco G. Pyoderma gangrenosum of the scalp treated with cyclosporine A. Int J Dermatol 2002;41:916-8.
14. Weenig RH, Davis MD, Dahl PR, Su WP. Skin ulcers misdiagnosed as pyoderma gangrenosum. N Engl J Med 2002;347:1414-8.
15. Harris AJ, Regan P, Burge S. Early diagnosis of pyoderma gangrenosum is important to prevent disfigurement. BMJ 1998;316:52-3.
16. Schofer H, Baur S. Successful treatment of postoperative pyoderma gangrenosum with cyclosporine. J Eur Acad Dermatol Venereol 2002;16:148-51.
17. Eichhorn PJ. Pyoderma gangrenosum. Dermatol Ther 2001;14:102-10.
18. Armstrong PM, Ilyas I, Pandey R, Berendt AR, Conlon CP, Simpson AH. Pyoderma gangrenosum: a diagnosis not to be missed. J Bone Joint Surg Br 1999;81:893-4.
19. Alam M, Grossman ME, Schneiderman PI, Blume RS, Benvenisty AI. Surgical management of pyoderma gangrenosum: case report and review. Dermatol Surg 2000;26:1063-6.
20. Lyon CC, Kirby B, Griffiths CE. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. Br J Dermatol 1999;140:562-4.
21. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000;284:1546-8.
22. Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002;3:149-58.
23. Su WP, Schroeter AL, Perry HO, Powell FC. Histopathologic and immunopathologic study of pyoderma gangrenosum. J Cutan Pathol 1986;13:323-30.
24. Hurwitz RM, Hasemann JH. The evolution of pyoderma gangrenosum: a clinicopathologic correlation. Am J Dermatopathol 1993;15:28-33.
25. Rosina P, Cunego S, Franz CZ, D'Onghia FS, Chieregato G. Pathergic pyoderma gangrenosum in a venous ulcer. Int J Dermatol 2002;41:166-7.
26. Khachemoune A, Kauffman CL. Diagnosis of leg ulcers. Internet J Dermatol 2002;1:2.
27. Chastain MA. The glucagonoma syndrome: a review of its features and discussion of new perspectives. Am J Med Sci 2001;321:306-20.
28. Coors EA, von den Driesch P. Pyoderma gangrenosum in a patient with autoimmune haemolytic anaemia and complement deficiency. Br J Dermatol 2000;143:154-6.
29. Bennett CR, Brage ME, Mass DP. Pyoderma gangrenosum mimicking postoperative infection in the extremities: a report of two cases. J Bone Joint Surg Am 1999;81:1013-8.
30. Jih DM, Khanna V, Somach SC. Bromoderma after excessive ingestion of Ruby Red Squirt. N Engl J Med 2003;348:1932-4.
31. Gilmour E, Stewart DG. Severe recalcitrant pyoderma gangrenosum responding to a combination of mycophenolate mofetil with cyclosporin and complicated by a mononeuritis. Br J Dermatol 2001;144:397-400.
32. Chow RK, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996;34:1047-60.
33. Brown BA, Parker CT, Bower KS. Effective steroid-sparing treatment for peripheral ulcerative keratitis and pyoderma gangrenosum. Cornea 2001;20:117-8.
34. Le Hello C, Bonte I, Mora JJ, Verneuil L, Noel LH, Guillevin L. Pyoderma gangrenosum associated with Wegener's granulomatosis: partial response to mycophenolate mofetil. Rheumatology (Oxford) 2002;41:236-7.
35. Kaminska R, Ikaheimo R, Hollmen A. Plasmapheresis and cyclophosphamide as successful treatments for pyoderma gangrenosum. Clin Exp Dermatol 1999;24:81-5.
36. Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol 1996;35:720-4.
37. Callen JP, Case JD, Sager D. Chlorambucil: an effective corticoidsparing therapy for pyoderma gangrenosum. J Am Acad Dermatol 1989;21(3 Pt 1):515-9.
38. Stone OJ. Sulfapyridine and sulfones decrease glycosaminoglycans viscosity in dermatitis herpetiformis, ulcerative colitis, and pyoderma gangrenosum. Med Hypotheses 1990;31:99-103.
39. Tusnadi A, Uhrin K, Benyei M, Krasznai G. Ulcerative colitis associated with pyoderma gangrenosum. Orv Hetil 1994;135:917-9.
40. Funakoshi N, Kanoh T, Uchino H, Miyake T, Kohriyama E, Oda T. The association of pyoderma gangrenosum with ulcerative colitis in Japan. Gastroenterol Jpn 1986;21:630-2.
41. Sanders CJ, Hulsmans RF. Successful treatment of pyoderma gangrenosum with topical aminosalicylic acid. Cutis 1993;51:262-4.
42. Lacy CF. Dapsone: drug information. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL, editors. Drug information handbook. 12th ed. Hudson (OH): Lexi-Comp; 2004-2005. p. 341-2.
43. Fukuhara K, Urano Y, Kimura S, Hori K, Arase S. Pyoderma gangrenosum with rheumatoid arthritis and pulmonary aseptic abscess responding to treatment with dapsone. Br J Dermatol 1998;139:556-8.
44. Khandpur S, Mehta S, Reddy BS. Pyoderma gangrenosum in two siblings: a familial predisposition. Pediatr Dermatol 2001;18:308-12.
45. Lacy CF. Clofazimine: drug information. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL, editors. Drug information handbook. 12th ed. Hudson (OH): Lexi-Comp; 2004-2005. p. 294-5.
46. Beurey J, Weber M, Delrous JL, Chaulieu Y. Pyoderma gangrenosum: clofazimine therapy. Ann Dermatol Venereol 1977;104:631-4.
47. Thomsen K, Rothenborg HW. Clofazimine in the treatment of pyoderma gangrenosum. Arch Dermatol 1979;115:851-2.
48. Kark EC, Davis BR, Pomeranz JR. Pyoderma gangrenosum treated with clofazimine: report of three cases. J Am Acad Dermatol 1981;4:152-9.
49. Mensing H. Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum): open clinical trial. Dermatologica 1988;177:232-6.
50. Dietzfelbinger H. Thalidomid und andere therapieansätze. In: Bartl R, Dietzfelbinger H, editors. Manual multiples myelom. Munich: Zuckerschwerdt, W., Verlag GmbH fur Medizin und Naturwissenschaften; 2002. p. 126-32.
51. Peuckmann V, Fisch M, Bruera E. Potential novel uses of thalidomide: focus on palliative care. Drugs 2000;60:273-92.
52. Lacy CF. Thalidomide: drug information. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL, editors. Drug information handbook. 12th ed. Hudson (OH): Lexi-Comp; 2004-2005. p. 1208-10.
53. Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002;59:1872-5.
54. Venencie PY, Saurai JH. Pyoderma gangrenosum in a child: treatment with thalidomide. Ann Pediatr 1982;29:67-9.
55. Hecker MS, Lebwohl MG. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol 1998;38:490-501.
56. Reynolds NJ, Peachey RD. Response of atypical bullous pyoderma gangrenosum to oral minocycline hydrochloride and topical steroids. Acta Derm Venereol 1990;70:538-9.
57. Gupta AK, Adamiak A, Chow M. Tacrolimus: a review of its use for the management of dermatoses. J Eur Acad Dermatol Venereol 2002;16:100-14.
58. Jolies S, Niclasse S, Benson E. Combination oral and topical tacrolimus in therapy-resistant pyoderma gangrenosum. Br J Dermatol 1999;140:564-5.
59. Petering H, Kiehl P, Breuer C, Kapp A, Werfel T. Pyoderma gangrenosum: successful topical therapy with tacrolimus (FK506). Hautarzt 2001;52:47-50.
60. Wenzel J, Gerdsen R, Phillipp-Dormston W, Bieber T, Uerlich M. Topical treatment of pyoderma gangraenosum. Dermatology 2002;205:221-3.
61. Nousari HC, Lynch W, Anhalt GJ, Petri M. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998;134:1509-11.
62. Michel S, Hohenleutner U, Mohr V, Landthaler M. Therapy-resistant pyoderma gangrenosum: treatment with mycophenolate mofetil and cyclosporine A. Hautarzt 1999;50:428-31.
63. Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003;98:1821-6.
64. Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstrom PM. Pyoderma gangrenosum associated with crohn disease: effect of TNF-α blockade with infliximab. Scand J Gastroenterol 2002;37:1108-10.
65. Triantafillidis JK, Cheracakis P, Sklavaina M, Apostolopoulou K. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 2002;37:863-5.
66. Grange F, Djilali-Bouzina F, Weiss AM, Polette A, Guillaume JC. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn's disease: rapid cure with infliximab. Dermatology 2002;205:278-80.
67. Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor a monoclonal antibody. Arch Dermatol 2001;137:930-3.
68. Lacy CF. Sodium hyaluronate: drug information. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL, editors. Drug information handbook. 12th ed. Hudson (OH): Lexi-Comp; 2004-2005. p. 1148-9.
69. Wollina U, Karamfilov T. Treatment of recalcitrant ulcers in pyoderma gangrenosum with mycophenolate mofetil and autologous keratinocyte transplantation on a hyaluronic acid matrix. J Eur Acad Dermatol Venereol 2000;14:187-90.
70. Trabucchi E, Pallotta S, Morini M, Corsi F, Franceschini R, Casiraghi A, et al. Low molecular weight hyaluronic acid prevents oxygen free radical damage to granulation tissue during wound healing. Int J Tissue React 2002;24:65-71.
71. Slevin M, Kumar S, Gaffney J. Angiogenic oligosaccharides of hyaluronan induce multiple signaling pathways affecting vascular endothelial cell mitogenic and wound healing responses. J Biol Chem 2002;277:41046-59.
72. Lacy CF. Becaplermin: drug information. In: Lacy CF, Armstrong LL, Goldman MP, Lance LL, editors. Drug information handbook. 12th ed. Hudson (OH): Lexi-Comp; 2004-2005. p. 148-9.
73. Braun-Falco M, Stock K, Ring J, Hein R. Topical platelet-derived growth factor accelerates healing of myelodysplastic syndrome-associated pyoderma gangrenosum. Br J Dermatol 2002;147:829-31.
74. Farris DR, Schutzer PJ, Don PC, Silverberg NB, Weinberg JM. Resolution of pyoderma gangrenosum after therapy with lyophilized bovine collagen matrix. Dermatology 2003;206:284-5.
75. Kolenik SA III, McGovern TW, Leffell DJ. Use of a lyophilized bovine collagen matrix in postoperative wound healing. Dermatol Surg 1999;25:303-7.
76. Fridey JL, Kaplan AA. Indications for therapeutic plasma exchange. UpToDate 11.1, 2003. Available from URL: www.uptodate.com.
77. Hagman JH, Carrozzo AM, Campione E, Romanelli P, Chimenti S. The use of high-dose immunoglobulin in the treatment of pyoderma gangrenosum. J Dermatolog Treat 2001;12:19-22.
78. Dobson CM, Parslew RA, Evans S. Superficial granulomatous pyoderma treated with intravenous immunoglobulin. J Am Acad Dermatol 2003;48:456-60.
79. Gleichmann US, Otte HG, Korfer R, Stadler R. Post-traumatic pyoderma gangrenosum: combination therapy with intravenous immunoglobulins and systemic corticosteroids. Hautarzt 1999;50:879-83.
80. Davis JC, Landeen JM, Levine RA. Pyoderma gangrenosum: skin grafting after preparation with hyperbaric oxygen. Plast Reconstr Surg 1987;79:200-7.
81. Jacobs P, Wood L, Van Niekerk GD. Hyperbaric oxygen as the only effective treatment in mutilating and resistant systemic vasculitis. Hematology 2000;5:167-72.
82. De Imus G, Golomb C, Wilkel C, Tsoukas M, Nowak M, Falanga V. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Am Acad Dermatol 2001;44:61-6.
83. Cliff S, Holden CA, Thomas PR, Marsden RA, Harland CC. Split skin grafts in the treatment of pyoderma gangrenosum: a report of four cases. Dermatol Surg 1999;25:299-302.